Trastuzumab deruxtecan
- Generic Name
- Trastuzumab deruxtecan
- Brand Names
- Enhertu
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1826843-81-5
- Unique Ingredient Identifier
- 5384HK7574
- Background
Trastuzumab deruxtecan is a HER-2 directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of metastatic, unresectable breast cancer. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuz...
- Indication
In the US, trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. It...
- Associated Conditions
- Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Adenocarcinoma, Metastatic Breast Cancer, Metastatic Breast Cancer With HER2 Positive, Unresectable Breast Cancer, Locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Locally advanced HER2-positive Gastric Adenocarcinoma, Metastatic HER2 Mutant Non-small Cell Lung Cancer, Metastatic HER2-low Breast Cancer, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic HER2-positive Gastric Adenocarcinoma, Unresectable HER2 Mutant Non-small Cell Lung Cancer, Unresectable HER2-low Breast Cancer, Unresectable HER2/Neu-positive Breast Cancer
- Associated Therapies
- -
Mum told by doctors bad back could be from 'lifting kids' is given horror cancer diagnosis
Jennifer McNeill, 34, initially misdiagnosed with muscular pain from lifting her kids, was later diagnosed with terminal breast cancer that had spread to her spine. Despite treatments like radiation and chemotherapy, she faces severe pain and mobility issues, focusing on her children's well-being. Her husband and friends have raised over £30,000 for hospice care.
ENHERTU gains conditional approval in China to treat NSCLC
Daiichi Sankyo and AstraZeneca's ENHERTU receives conditional approval from China's NMPA for treating unresectable or metastatic NSCLC with HER2 mutations, marking the fourth approval in China for ENHERTU across different tumor types. The approval is based on Phase II studies DESTINY-Lung02 and DESTINY-Lung05, showing ORRs of 49% and 58.3% respectively.
Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant ...
AstraZeneca and Daiichi Sankyo's Enhertu received conditional approval in China for treating HER2-mutant metastatic NSCLC, based on DESTINY-Lung02 and DESTINY-Lung05 trials. Enhertu demonstrated a confirmed objective response rate of 49.0% in DESTINY-Lung02 and 58.3% in DESTINY-Lung05, with no new safety concerns. This marks the first HER2-directed therapy approved in China for this indication.
Related Clinical Trials:
Enhertu by AstraZeneca, Daiichi wins new approval in China
AstraZeneca's Enhertu receives approval in China as the first HER2-directed therapy for HER2-mutant metastatic non-small cell lung cancer, based on phase 2 trial results. This marks the fourth approval in China for Enhertu, co-developed with Daiichi Sankyo, across three different tumor types.
Daiichi Sankyo to Boost ADC Cancer Drug Production, COO Says
Daiichi Sankyo boosts production of newer-generation cancer therapies, including antibody drug conjugates (ADCs), across Japan, Europe, and the US. The ADCs, likened to guided missiles targeting cancerous cells, have potential to replace chemotherapy. Daiichi Sankyo partners with AstraZeneca and Merck & Co. for ADC development, with Enhertu on track for over $3.4 billion in revenue this fiscal year.
Shining a Light on the Importance of Prevention Strategies During Breast Cancer Awareness Month
Breast Cancer Awareness Month emphasizes early detection, personalized treatment, and addressing disparities. Personalized medicine uses NGS testing and targeted therapies like capivasertib. HER2 ultra-low classification expands T-DXd eligibility. Research aims to reduce treatment toxicities, especially in Black women. Early detection strategies include mammograms and recognizing symptoms. Post-treatment care focuses on regular oncologist visits and managing long-term AEs.
New Hope Against Breast Cancers That Spread to the Brain
Enhertu, a targeted chemotherapy drug, significantly extends lives of advanced breast cancer patients with brain tumors, with over 60% surviving 12 months without tumor growth and 70% seeing tumor shrinkage.
Oncolytics targets accelerated approval for oncolytic virus therapy
Oncolytics Biotech seeks accelerated approval for pelareorep, its lead cancer therapy, based on positive Phase II BRACELET-1 trial data. A registrational Phase II trial is planned for 2025, evaluating pelareorep combined with paclitaxel in breast cancer patients. Oncolytics' stock rose 18.22% on the news, reflecting investor optimism. Oncolytic virus therapies are projected to see significant growth, from $114m in 2023 to $2.4bn by 2029.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath